AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Use of Neurotrophic Factors in Treating Memory Loss and Neurodegenerative Disease

Technology Application

The method is useful in the therapy of defective, diseased, and damaged neurons in the brain for normal aging or in treating neurodegeneration of the type associated with Alzheimer's disease and Parkinson's.

Detailed Technology Description

UC San Diego researchers have shown that nervous system growth factors BDNF and NT-4/5 have efficacy in reversing age-related memory impairment and enhance neuronal structure when delivered to the entorhinal cortex. The invention includes the specific administration protocols needed to effectively deliver this factor with minimal side effects.

Supplementary Information

Patent Number: US7776320B2
Application Number: US2006431436A
Inventor: Tuszynski, Mark H.
Priority Date: 31 Dec 2001
Priority Number: US7776320B2
Application Date: 10 May 2006
Publication Date: 17 Aug 2010
IPC Current: A01N006300 | A61K003822 | A01N004304 | A01N006500 | A61K003170 | A61K003818 | A61K004800 | A61P002500 | A61P002528
US Class: 4240931 | 4240932 | 42409321 | 514044R | 514044
Assignee Applicant: The Regents of the University of California
Title: Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
Usefulness: Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
Summary: The method is useful for stimulating or supporting cortical neurons in a subject's brain, where the subject is human or aged. The human is suffering from Alzheimer's disease, and the disease is ameliorated by stimulation of growth or activity in neurons of entorhinal cortex. The disease is ameliorated by reversal of deficits in cognitive function associated with Alzheimer's disease (claimed).

Industry

Disease Diagnostic/Treatment

Sub Group

Other Disease

Application No.

7776320

Others

State Of Development

The genes have been tested successfully in animal models, and the administration protocols have been tested successfully in human clinical trials.

Related Materials

Tuszynski MH, Mafong E, Meyer S. Central Infusions of Brain-Derived Neurotrophic Factor and Neurotrophin-4/5, but not Nerve Growth Factor and Neurotrophin-3, Prevent Loss of the Cholinergic Phenotype in Injured Adult Motor Neurons. Neuroscience. 1996 Apr;71(3):761-71.
Lu P, Blesch A, Tuszynski MH. Neurotrophism Without Neurotropism: BDNF Promotes Survival but not Growth of Lesioned Corticospinal Neurons. J Comp Neurol. 2001 Aug 6;436(4):456-70.
Tobias CA, Shumsky JS, Shibata M, Tuszynski MH, Fischer I, Tessler A, Murray M. Delayed Grafting of BDNF and NT-3 Producing Fibroblasts into the Injured Spinal Cord Stimulates Sprouting, Partially Rescues Axotomized Red Nucleus Neurons from Loss and Atrophy, and Provides Limited Regeneration. Exp Neurol. 2003 Nov;184(1):97-113.

Tech ID/UC Case

19509/2001-109-0

Related Cases

2001-109-0

Country/Region

USA

For more information, please click Here